STERIS' Q3 Earnings on Deck: What's in Store for the Stock?

Core Insights - STERIS plc (STE) is set to announce its third-quarter fiscal 2026 results on February 4, with expectations of strong performance based on previous earnings trends [1][9] - The company reported adjusted EPS of $2.47 in the last quarter, exceeding the Zacks Consensus Estimate by 3.8%, and has beaten earnings estimates in three of the last four quarters [1][9] Q3 Estimates for STE - The Zacks Consensus Estimate for revenues is $1.48 billion, reflecting an 8% increase from the same quarter last year [2][9] - The estimated EPS for the quarter is $2.53, indicating a year-over-year increase of 9.1% [2][9] Estimate Revision Trend - Earnings estimates have remained stable at $2.53 per share over the past 30 days, indicating confidence in the company's performance [3] Healthcare Segment Performance - Growth across all categories in the Healthcare segment is expected to continue, supported by strong recurring revenue streams and backlog strength [4] - The Healthcare capital equipment segment is projected to see order growth, with revenues expected to rise by 8.1% year over year [5][9] Applied Sterilization Technologies (AST) - The AST segment is anticipated to experience organic revenue growth, driven by stable global MedTech customers and increased bioprocessing demand [6] - Revenues for the AST segment are expected to increase by 8.1% year over year [7][9] Life Sciences Segment - The Life Sciences segment saw significant growth in consumables and services, with capital equipment shipments increasing by 39% in the previous quarter [8] - This positive trend is expected to continue, with revenues projected to rise by 8% year over year [8][9]